ARPO - Aerpio Pharmaceuticals, Inc.
| Previous Close | 0.6925 |
| Open | 0.6930 |
| Bid | 0.6971 x 900 |
| Ask | 0.6990 x 1300 |
| Day's Range | 0.6900 - 0.7000 |
| 52 Week Range | 0.4500 - 4.2500 |
| Volume | 62,868 |
| Avg. Volume | 304,655 |
| Market Cap | 28.412M |
| Beta (5Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6730 |
| Earnings Date | Nov 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
- Simply Wall St.
Those Who Purchased Aerpio Pharmaceuticals (NASDAQ:ARPO) Shares A Year Ago Have A 80% Loss To Show For It
While it may not be enough for some shareholders, we think it is good to see the Aerpio Pharmaceuticals, Inc...
- Business Wire
Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a Phase 1b trial showing the potential of a topical ocular formulation of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower intraocular pressure (IOP) with minimal conjunctival hyperemia when combined with standard-of-care prostaglandin therapy. The data were presented at the Glaucoma 360 New Horizons Forum 2020, on February 7, in San Francisco.
- Business Wire
Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients in that cohort with ocular hypertension (OHT) or primary open angle glaucoma (POAG).
- Insider Monkey
Hedge Funds Are Buying Aerpio Pharmaceuticals, Inc. (ARPO)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Simply Wall St.
Here's Why We're A Bit Worried About Aerpio Pharmaceuticals's (NASDAQ:ARPO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- American City Business Journals
Cincinnati firm’s stock jumps amid C-suite shakeup, possibility of sale or merger
The price of stock in Aerpio Pharmaceuticals Inc. soared this morning following disclosure of a C-suite shakeup and an announcement that the board is exploring the potential for a sale, merger or other transaction.
- Zacks
All You Need to Know About Aerpio Pharmaceuticals, Inc. (ARPO) Rating Upgrade to Buy
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Business Wire
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The primary endpoint of the trial is ocular safety and tolerability, with IOP lowering as the key pharmacodynamic endpoint. “POAG is characterized by increased IOP leading to optic nerve and neuroretina anomalies and progressive visual field defects,” said Kevin Peters, M.D., Chief Scientific Officer of Aerpio Pharmaceuticals.
GuruFocus.comWall Street Sees 3 Falling Knives Rebounding Within 52 Weeks
The following companies are falling knives since their share prices have declined more than 59% over the past year through May 13. Wall Street issued a recommendation rating of overweight to buy for all three stocks, increasing the likelihood of them outperforming the S&P 500 index within 52 weeks. Warning! GuruFocus has detected 5 Warning Signs with CLDX.
- Business Wire
Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma in the Second Quarter of 2019
- Business Wire
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting
- Business Wire
Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will present data demonstrating the role of VE-PTP in the conventional outflow pathway and the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, as a treatment for open-angle-glaucoma. The data are to be presented at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting on April 29 in Vancouver, British Columbia.
- Zacks
Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Business Wire
Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
- Business Wire
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration of AKB-9778 twice daily did not meet the study’s primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score (DRSS) compared to placebo.
- GuruFocus.com
Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018
Aerpio Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 2 Warning Signs with IRMD. For the last quarter Aerpio Pharmaceuticals Inc reported a revenue of $0.00 million, compared with the revenue of $0.00 million during the same period a year ago.
- Business Wire
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy Expected in March 2019
